TRT · HRT

Growth marketing for TRT & hormone brands

Acquisition for testosterone and hormone-therapy brands in the most ad-restricted corner of health - where the winning move is channel diversification, not paying the restricted-auction premium.

Typical CAC $180–$300 Compliance-first Setup in 5 days
The short answer Helped launch a $99/mo all-inclusive TRT offer that cut CAC 54%. We only work in health, so the playbook, creative, and compliance are purpose-built for trt & hormone - not adapted from a generic DTC template.

Market context

The global TRT market is ~$2.4–2.5B in 2025–2026, but the real story is the DTC/telehealth layer: online men’s-health platforms have blown past $400M in US spend and grow ~9%/year, with Hims reporting 2.4M+ subscribers in 2025 (+31% YoY). The 2026 urgency is regulatory: the FDA removed testosterone’s cardiovascular black-box warning (easing prescribing), demand from men in their 30s–40s is exploding, and the DEA’s fourth telemedicine extension keeps the no-prior-exam pathway open through Dec 31, 2026 - but testosterone is Schedule III, so prescribing still legally requires a synchronous video visit and documented hypogonadism.

The trt & hormone growth playbook

Google and Meta auto-flag “testosterone/TRT/HRT” ads, so brands leaning on a single paid channel are one policy update away from zero.

Google + YouTube + podcast carry the load; Meta is a minefield

Meta’s 2025 restrictions strip lower-funnel optimization from clinics linking to patient portals, and you cannot name testosterone or promise a prescription in creative - so Meta works only for top-funnel symptom/education driving to a compliant quiz. Google Search is the workhorse for high-intent queries but requires LegitScript and Restricted-Drug-Term compliance. Podcast/influencer (men’s-health, fitness, longevity) and YouTube pre-roll are highest-leverage - they sell the education narrative natively without tripping substance policies.

Sell the symptom and the evaluation, never the molecule

Winning hooks lead with the felt experience of low-T: fatigue, low libido, brain fog, stubborn belly fat, "not feeling like yourself at 40" - routing to a free symptom quiz with the CTA on assessment, not the drug. Keep testosterone, dosages, and "boost your T" claims out of copy and imagery. Frame outcomes as "find out if your levels are low," which converts the deliberating buyer (a 2–6 week consideration cycle) while staying in policy.

Quiz → at-home lab → consult → membership

The proven structure: symptom quiz as lead magnet, an at-home or lab-draw panel to confirm eligibility (often $65–$99 as a low-friction tripwire), a synchronous video consult, then a monthly membership bundling labs + medication + provider access. Tiering works - a low entry tier (~$25/mo + meds) and premium (~$99–$149/mo). Automating labs end-to-end is critical; manual lab handling is the single biggest killer of TRT retention.

Monitoring is the moat

Unlike ED (episodic) or GLP-1 (weight-goal churn), TRT is ongoing-to-lifelong once dialed in, so LTV is structurally high and retention is the whole game. Build around a scheduled lab-monitoring cadence (baseline, ~6–8 week titration, then quarterly) that protects safety and creates re-engagement. Ancillary prescriptions (HCG, anastrozole, PT-141) raise AOV and stickiness; tightly qualified programs see 2–3× the retention of loose ones.

Compliance landmines

Watch for thisTestosterone and hormone keywords trigger automatic review and disapprovals. Prescription drug promotion rules apply; claims about virility, performance, or body composition are high-risk. Telehealth CAC benchmarks: what top brands pay per patient →

Common mistakes in trt & hormone

  • Running creative that names testosterone, shows vials/needles, or promises "boost your T" - an instant Meta/Google rejection that can nuke the account.
  • Treating TRT like an unregulated supplement and ignoring that it’s a Schedule III controlled substance requiring a synchronous video visit and documented diagnosis.
  • Positioning as muscle-building / "get jacked," which triggers PED policy flags and attracts non-clinical buyers who churn.
  • Over-promising outcomes ("cure fatigue," "10x your energy") instead of framing an evaluation.
  • Handling labs manually or skipping the monitoring cadence, creating refill-stage friction and safety gaps that collapse retention.

What good looks like

  • Fully-loaded CAC $180–$300 per acquired patient
  • Symptom-quiz-to-lab-kit ~25–40%; consult-to-membership ~50–70%
  • 12-month retention 70–85%; payback under 6 months
  • LTV ~$1,500–$3,000+ (near-lifelong therapy + ancillaries); LTV:CAC ≥ 3:1

Segments we work in

Men’s TRT telehealthWomen’s HRT / menopauseLongevity / hormone-optimization conciergeThyroid & endocrine optimizationSexual-wellness adjacency (PT-141, HCG)

What we do for trt & hormone brands

Compliant paid media

Meta, Google & TikTok, structured for this vertical’s auction.

Learn more →

In-house creative

20+ compliant variants a month, built around winning angles.

Learn more →

CRO & funnels

Quiz funnels and landers tuned to LTV and payback.

Learn more →

TRT & hormone marketing FAQ

Fully-loaded CAC typically runs $180–$300, with qualified leads at $15–$50. Because TRT subscriptions ($99–$300/month) are extremely sticky once a patient is titrated, payback under ~1.5 months with 70%+ retention is a strong position.

It’s heavily restricted - testosterone/TRT/HRT ads are auto-flagged and frequently disapproved, and prescription-drug promotion rules apply. Sustainable TRT brands diversify into SEO, content, and referral so no single policy update can zero out acquisition.

Not the drug itself - you can advertise the clinic, the consultation, and the evaluation, but you cannot name testosterone, promise a prescription, or make treatment claims. Meta restricts lower-funnel optimization for clinics tied to patient portals, and Google requires LegitScript plus Restricted-Drug-Term compliance. The compliant play is symptom-and-quiz creative on Meta/YouTube and certified, evaluation-framed Search on Google.

Testosterone is Schedule III, so the DEA’s fourth extension (through Dec 31, 2026) is what currently allows initiating TRT without a prior in-person exam - via real-time video, for a legitimate medical purpose, in compliance with state law. A permanent DEA rule expected before end of 2026 will likely add registration and identity-verification requirements, so build the compliance stack now.

Ready to lower CAC on your trt & hormone brand?

A 30-minute call with a senior strategist. Free account audit included. No pitch deck - a written plan you can keep, whether you work with us or not.

Book a free strategy call
30 minutes Free account audit Written plan either way
Book a free strategy call